Updates are available Erratum dated 2017-09-07
Click to view Erratum: https://doi.org/10.1007/s10620-017-4729-1
-
Authors
Pimentel, M.
Cash, B. D.
Lembo, A.
Wolf, R. A.
Israel, R. J.
Schoenfeld, P.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01543178 at ClinicalTrials.govDocuments that mention this clinical trial
Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
https://doi.org/10.1007/s10620-017-4598-7
-
Funding
Funding for this research was provided by:
Salix Pharmaceuticals
- License Information
-
More Information
Article History
Received: 2 December 2016
Accepted: 29 April 2017
First Online: 6 June 2017
Change Date: 7 September 2017
Change Type: Erratum
Change Details: An erratum to this article has been published.
Compliance with ethical standards
:
: M. Pimentel reports serving as a consultant for and receiving research funding from Salix Pharmaceuticals. In addition, Cedars-Sinai Medical Center has a licensing agreement with Salix Pharmaceuticals. B.D. Cash reports serving as a speaker, consultant, and an advisory board member for Salix Pharmaceuticals. A. Lembo reports serving as a consultant and an advisory board member for Salix Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Allergan plc, Ardelyx, and Valeant Pharmaceuticals. R.A. Wolf is a former employee of Salix Pharmaceuticals. R.J. Israel is an employee of Salix Pharmaceuticals or its affiliates. P. Schoenfeld reports serving as a consultant and advisory board member for Salix Pharmaceuticals, Ironwood Pharmaceuticals, Allergan, and Commonwealth Laboratories, a division of Valeant Pharmaceuticals North America LLC.
: All procedures performed in the study were in accordance with the International Standard of Good Clinical Practice procedures and with the principles of the Declaration of Helsinki (1964) and relevant amendments. The protocol was approved by all institutional review boards and ethics committees at participating sites.
